By Chris Wack
Shares of Protagenic Therapeutics doubled after it agreed to be bought by Phytanix Bio in an all-stock transaction.
The company's stock was 133% higher, at $7.07, in morning trade, but still down 67% in the past 12 months.
The combined entity will be called Phytanix Inc.
As calculated on a fully diluted basis, Protagenic shareholders post-combination will own 35% of the new company, and Phytanix Bio stockholders will own 65% of the company.
Phytanix Bio is a pharmaceutical company specializing in the development of medicines manufactured from cannabinoid and cannabinoid-like molecules.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
May 19, 2025 10:06 ET (14:06 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.